Tags Posts tagged with "Sean Spicer"

Sean Spicer

0 3148

There seems to be some confusion amongst the leaders of this incredible country.

In late February, White House press secretary Sean Spicer made an uneducated and informed connection between the opioid addiction crisis we currently face and recreational cannabis.

Spicer said, “There’s a big difference between that and recreational marijuana. I think that when you see the opioid addiction crisis blossoming in so many states around this country, the last thing we should be doing is encouraging people. There is still a federal law we need to abide by in terms of when it comes to recreational marijuana.”

Providing Real Facts…Not the Alternative Kind

In January, the National Academies of Sciences, Engineering and Medicine released a review of 10,000 medical cannabis studies published since 1999. The results strongly support the use of cannabis for the treatment of chronic pain.

In 2014, John Hopkins published a report that found the annual number of deaths from prescription drug overdose is 25% lower than in states where medical marijuana remains illegal.

Several reports actually link the opioid crisis we are currently facing to big pharmaceutical companies that liberally prescribed drugs like Oxycontin and Vicodin.

In late December, Department of Justice said several former employees of Insys Therapeutics (INSY), including its former CEO and president, had been arrested and charged with bribing doctors and defrauding health insurers to push prescriptions of Subsys, a fentanyl sublingual spray that has led to countless overdoses.

Biotech Stocks to Watch

The opioid crisis the United States faces combined with recent breakthroughs in research pertaining to the medical benefits of cannabis have created several attractive opportunities for biotech investors.

Some of the companies investors should be watching Future Farm Technologies Inc. (FFT.CN) (FFRMF), Vinergy (VIN.CN) (VNNYF), and InMed Pharmaceuticals Inc. (IN.CN) (IMLFF).

2 3026

The marijuana industry was recently shaken up after White House Press Secretary Sean Spicer said he expects the Department of Justice to boost enforcement of federal laws restricting recreational cannabis, even in states where it is legal already. Along with the District of Columbia, eight states have legalized recreational use among adults. That means one in five American adults can smoke, vape, drink, or eat cannabis under state law.

Over 50% of the nation’s states have legalized medical cannabis despite federal laws restricting its sale. According to Cowen & Co., the industry is estimated to be worth more than $6 billion and will hit $50 billion by 2026. Derek Peterson, CEO of marijuana cultivator Terra Tech Corp. stated, “Today’s news coming out of the administration regarding the adult use of cannabis is, of course, disappointing. We have hoped and still hope that the federal government will respect states’ rights in the same manner they have on several other issues.”

Spicer sought to analyze the prospect of federal enforcement for medical, versus recreational, marijuana use, saying “there’s still a federal law that we need to abide by when it comes to recreational marijuana and other drugs of that nature.” Spicer’s statements revived industry concern that first arose when Republican President Donald Trump’s short-list of potential attorney general nominees emerged. The final pick, former senator Jeff Sessions of Alabama has long opposed cannabis use, but is a major proponent of state’s rights.

In his mid-January confirmation hearing, Sessions said he wouldn’t “commit to never enforcing federal law” but added that “absolutely it’s a problem of resources for the federal government.” He said that if Congress felt cannabis possession should no longer be illegal, it “should pass a law.” Trump has similarly gone back and forth on the issue of legalization. A restriction on the industry would reverse existing federal policy and go against public opinion. The Obama administration largely deferred to the states, instead focusing on preventing distribution to minors, blocking sales across state lines, and keeping it out of the hands of gangs and criminals. A recent poll from Quinnipiac University found 71% of voters think “the government should not enforce federal laws against marijuana in states that have legalized medical or recreational use.”

0 2436

On Thursday, Press Secretary Sean Spicer said the President understands the value of medical cannabis for those in need, however, recreational cannabis or adult-use is an issue for the Department of Justice to provide further clarification.

Spicer seemed to link marijuana use to the opioid addiction crisis plaguing the United States. Despite his un-educated attempt to link cannabis use to opioid addiction, a Johns Hopkins report published in August 2014 determined that states with legal marijuana programs have fewer prescription overdose deaths.

In January 2017, the National Academies of Sciences, Engineering and Medicine also released a review of 10,000 medical cannabis studies published since 1999. These data associated with these studies provide substantial evidence that supports the use of cannabis or its extracts for the treatment of chronic pain.

In November 2015, Forbes Magazine reported about a 60-Minutes episode that blamed the opioid crisis entirely on big pharmaceutical companies.

Cannabis advocates need to continue make their voices heard by respective state and local officials and legislatures to push back on this.

Stocks Under Pressure

Over the last few months, we have de-risked our leverage to the United States cannabis industry while increasing leverage to Nasdaq-traded biotech companies and Canadian cannabis companies.

We continue to remain favorable on the United States cannabis industry but expect to see weakness in the near-term and continue to focus on Canadian traded cannabis stocks as well as the biotech leaders.

Stocks we are watching and remain most favorable on include: GW Pharmaceuticals (GWPH), Emblem Corp (EMC.V) (EMMBF), Kush Bottles (KSHB), Canopy Growth (TWMJF) (WEED.TO), Zynerba Pharmaceuticals (ZYNE), Aphria (APHQF), Reliq Health (RQHTF) Aurora (ACBFF), VPR Brands (VPRB), Lexaria (LXRP), VinergyRes (VIN.CN), and Canabo Medical (CMM.V) (CAMDF).

0 5077

@WolfOfWeedST

With the Trump Administration in complete disarray and touting debunked information about Cannabis & Opioid connections we at MarijuanaStocks.com decided to play a little game of devils advocate. The fact remains that the Trudeau administration remains progressive and is doing what all governments should be doing i.e. listening to its people. Canadians are in overwhelming support of legal cannabis markets which is why they legalized medical marijuana last year. This year the country plans on legalizing recreational use in an effort to crush black markets, create jobs, industry and position itself as a worldwide leader in cultivation. With a completely legal market Canada will face one major issue that will reap major benefits to public cultivation companies. That issue being one of supply and demand. Already operating at a deficit and coupled with an approval process by Health Canada that can take years we foresee investors sending their capital north of the border unless they are invested in companies insulated by restrictions on the recreational markets. Those US companies being: Construction for Cultivation, manufacturers of products, companies monetizing industrial Hemp’s many uses, CBD manufacturers, technology & media services (like us).

One of the highly anticipated events of 2017 is the tabling of legislation as it relates to a legal recreational cannabis program in Canada. This development is expected to take place in the Spring.

During December, a federal task force released its long-awaited recommendations relating to the legalization of recreational marijuana. The report was prepared by a committee comprised of nine members who have worked together since June.

All Eyes on Legislation this Spring

When Canada legalizes recreational marijuana, demand is going to increase significantly, however it will take time for the program to be up and running. For this reason, Canadian licensed medical cannabis producers have been aggressively raising capital to make acquisitions and to increase production capacity.

One of the largest fundamental changes within the Canadian cannabis sector over the last year relates to the amount of capital entering the industry as well as the source of the capital. The capital entering the industry is not only larger but smarter too; these investors and firms are long-term holders that see the bigger picture.

Five Opportunities to Watch

The Canadian cannabis industry has continued to be a bright spot for cannabis investors and 2017 has already provided investors with strong investment returns.

This sub-sector of the cannabis industry has been on fire since July 2016 and the increased interest has been fueled by anticipation of Canada becoming the first G-7 nation to legalize recreational cannabis.

Although the Canadian cannabis industry offers investors a lot of opportunity, it does not come without risk. Many of the companies levered to this sector have seen a significant rally over the last six months while some have not fared as well.

We want highlight five Canadian cannabis stocks that should be on every investors radar. From

The Green Organic Dutchman’s second round of financing closes today at 5pm and investors can still reach out to support@sbpartners.io if they still want to access this opportunity.

Terms of the offering are as follows: The company is selling units at $1.15 CAD per unit and the minimum purchase level is 5,000 units. Each unit consists of one common share and one full share purchase warrant. Each warrant provides the investor to purchase shares of The Green Organic Dutchman at $2.15 for the next two-years no matter what price the shares are trading at.

The Green Organic Dutchman produces farm grown pharmaceutical grade organic cannabis. The company has differentiated itself from the competition by producing high-quality organic cannabis that sells for a higher price and has better profit margins. The company is led by a management team that has a proven track record of success with licensed Canadian medical cannabis producers such as OrganiGram and Emblem Corp.

Aphria (APH.V: TSX Venture) (APHQF: OTC) has been one of the top performers this year and the shares are up approximately 30% YTD. The shares moved considerably higher after the company received conditional approval to up-list on the TSX exchange and we remain favorable on the company’ long-term outlook.

In early February, Aphria announced a $50 million private placement at $5.00 a share and this transaction is expected to close this week. The company expects that 80% of the net proceeds will be allocated towards the currently unfunded portion of Part IV Expansion, with the balance being allocated towards strategic investments.

The Part IV expansion will increase Aphria’s capacity from 300,000 to 1 million square feet. In addition, the company’s infrastructure will grow to over 250,000 square feet which is necessary to service the expected 70,000 kilograms of eventual annualized harvests. The project includes 700,000 square feet of Dutch style greenhouses, 230,000 square feet of infrastructure, including new Level 9 vaults, automation for all the greenhouses, processing areas, warehouse facilities, a 15 MW power and heat co-generation facility and security consistent with ACMPR standards.

Aphria anticipates completion of Part IV within 12 months, Health Canada approvals within 4 months of completing the expansion and first harvest within 4 months after such approvals.

In December 2016, Aphria invested $8.4 million in Canabo Medical Inc. (CMM.V: TSX Venture) (CAMDF: OTC) at $1.40 a share. Canabo is another stock we are very favorable as the shares trade at an almost 40% discount to the level at which Aphria invested at.

Canabo owns and operates the largest line of medical cannabis clinics in Canada and we expect to see the company continue to expand its footprint across Canada.

CMM.V is trading at $0.85 after the shares rallied more than 13% on above-average volume. We highlighted the company last month as an attractive opportunity and continue to see upside to current levels. The company’s United States symbol, CAMDF is trading below $0.67 after a 16.4% rally and we continue to see upside to these levels.

PharmaCan Capital (MJN: TSX Venture) (PRMCF: OTC) has the top performing licensed Canadian medical cannabis producer this year and the shares are up 92.6% YTD. The company does business as Cronos Group and in 2016, it sold one of its properties to NYSE-traded Innovative Industrial Properties (IIPR).

The shares were under pressure last week after the company announced a $15 million private placement at $2.25 a share. MJN.V quickly bounced back and rallied more than 40% over the few trading days.

The company’s wholly-owned subsidiary, In The Zone, recently received approval from Health Canada to sell medical cannabis. This comes while its other wholly-owned subsidiary, Peace Naturals is positioned to capitalize on the recent medical cannabis legislation in Germany through its export relationship with Pedanios GmbH.

Although the shares have recent run significantly higher, we have become increasingly favorable on the company over the last quarter and continue to monitor trading closely. Become a Technical420 Premium Member to keep up with our analysis.

Canopy Growth Corp. (WEED.TO: TSX) (TWMJF: OTC) continues to be the Canadian medical cannabis leader and we view the company as one of the best long-term cannabis investments.

The company recently completely the acquisition of Mettrum Health, which significant expanded its product line and led to a surge in revenue. The market did not initially respond favorable to Canopy earnings report and the shares recorded its largest drop of the year.

During the quarter, Canopy Growth recorded $3 million in net income off $9.8 million in revenue and total revenue increased 15% when compared to the prior quarter and 180% when compared to the same period last year.

During the quarter, the company sold 1,245 kilograms and kilogram equivalents at an average price of $7.36 per gram, up from 462 kilograms at an average price of $7.34 per gram during the prior year period.

The company recorded strong growth on pretty much all metrics and as of December 31st , Canopy Growth reported to have over 29,000 registered patients which is more than 260% higher than the number of patients as of December 31, 2015.

Canopy has recaptured most of its losses and we continue to remain favorable and monitor trading activity closely. WEED.TO recently traded into the $13.20 range and the shares are currently trading at $12.64. We remain favorable on Canopy Growth and this company should be on every cannabis investor radar screen.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements